Objectives: In a prospective 4-year study, we evaluated the progression of motor and non-motor symptoms in Parkinson's disease (PD) patients with Asian-specific LRRK2 risk variants and non-carriers.
INTRODUCTION
PD is a common neurodegenerative disease with clinical heterogeneity and diverse causative factors. At least nine genes have been implicated in PD, with overlapping pathological features (1) . The common LRRK2 G2019S mutation is located in the kinase domain, possibly associated with an increase in kinase activity (2) . Clinically, patients harboring G2019S share considerable similarity with sporadic PD patients (3) . The polymorphic variants G2385R, R1628P, and S1647T are associated with increased risk for PD in the Asian population (4) .
A recent study showed that PD patients with the Asian LRRK2 variants experienced greater progression in motor symptoms (5) . However, other aspects of the disease, including non-motor symptoms which greatly account for the decline of quality of life in PD, were not evaluated during the follow-up. To address this gap in knowledge, we conducted a longitudinal study to evaluate the progression of both motor and non-motor features in Asian LRRK2 PD carriers compared to non-carriers.
METHODS

Study Population
PD patients were assessed prospectively from movement disorder outpatient clinics in Singapore General Hospital over a 4-year period. The clinical diagnosis was based on the UK PD Brain Bank criteria (6) . PD patients who received deep brain stimulation surgery or whose PD diagnosis was amended during the follow-up period were excluded. Our study was approved by SingHealth Centralized Institutional Review Board, and all methods were performed in accordance with the relevant guidelines and regulations. Written informed consent was obtained from all subjects.
Genetic Analyses and Grouping Patients
Three LRRK2 variants (R1628P, S1647T, and G2385R) were genotyped by TaqMan real-time PCR. Based on the genotyping results, we grouped the patients into LRRK2 risk variant carriers (R1628P, S1647T, and/or G2385R missense variants) and noncarriers (wild type for all the LRRK2 variants).
Data Collection and Assessments
Demographic data were collected from all subjects. The levodopa equivalent daily dose was calculated by standardized formula (7) . Modified Hoehn and Yahr (H&Y) staging scale, Unified Parkinson's Disease Rating Scale (UPDRS) part III, Non-motor Symptom Scale (NMSS), Parkinson's disease Questionnaire-39 item version (PDQ-39), and Elderly Cognitive Assessment Questionnaire were applied to assess disease severity, motor symptoms, non-motor burden, quality of life, and cognitive impairment, respectively. UPDRS scores were obtained during the "on" medication period. There are nine domains in NMSS, including cardiovascular domain, sleep/fatigue, mood/apathy, perceptual problems/hallucinations, attention/memory, gastrointestinal, urinary, sexual function, and miscellaneous (8) . The overall non-motor burden (NMSS total score) is calculated by the sum of all the domain scores. PDQ-39 comprises 39 questions categorized in 8 domains (mobility, activities of daily living, emotional well-being, stigma, social support, cognitive impairment, communication, and bodily discomfort). Summary index (SI) is calculated for the total PDQ-39 scale (PDQ-39 SI) and the eight domains. A higher NMSS score and PDQ-39 SI indicate greater NMS burden and worse quality of life. A lower Elderly Cognitive Assessment Questionnaire score suggests greater cognitive impairment. The assessments were conducted by one clinical research staff with formalized training on the same day at baseline and follow-up visits. The follow-up visits were carried out yearly, and the final visit was up to 4 years. Both the rater and patients were blinded to genotype status.
Statistical Analysis
Frequency together with proportion was reported for categorical data, while median together with interquartile range was reported for continuous variables at baseline. Fisher's exact test was performed to compare categorical data at baseline among different groups of patients, while the Mann-Whitney test was carried out to compare the distribution of these continuous variables between different groups of patients. The differences from baseline in patients with risk variants were compared to the control group by means of generalized estimating equation model. Each score was standardized; an interaction term between visit and group was examined for its significance by means of GEE model. Data analysis was performed in Stata V13.1 (Stata Corp, College Station, TX, USA) and R 3.1.3 (www.r-project.org) with significance level of 5%. 
RESULTS
A total of 202 PD patients, including 133 patients with risk variants and 69 controls without risk variants, were assessed prospectively over a 4-year period. One hundred thirty-three patients carried at least one of the three risk variants. The G2385R frequency was 6.8% (17 patients), the R1628P frequency was 8.4% (21 patients), while the S1647T frequency was 53.0% (132 patients). At baseline, there were no significant differences in the demographic characteristics, UPDRS score, and NMSS score between risk variant carriers and non-carriers (Table 1) . GEE model analysis showed that mean H&Y scale increased more substantially after 4 years onwards in patients with risk variants (risk variants carriers, 0.65; non-carriers, 0.06, P = 0.041). Consistently, risk variant carriers showed faster progression of UPDRS postural and gait score than non-carriers from baseline to year 4 follow-up (visit 5), although the differences were not significant (risk variants carriers, 0.83; non-carriers, 0.54, P = 0.348) ( Table 2, Figures 1, 2) . In terms of non-motor symptoms, at year 1 follow-up (visit 2), scores of non-carriers in mean NMSS domain 3 score (mood/apathy), mean PDQ-39 domain 3 SI (emotional wellbeing), and total number of NMS items were simultaneously reduced. These score changes were significantly different between non-carriers and risk variant carriers (Table 2, Figures 3, 4) . However, the progression of non-motor symptoms was not significantly different after year 1 between the two groups. 
DISCUSSION
Our long-term follow-up revealed greater disease severity after 4 years onwards using Modified H&Y staging scale, which grades the overall motor function of the patients. In particular, postural instability contributes significantly to the scores in H&Y staging (9) . Consistently, the trend is notable that patients with risk variants in our study present with higher UPDRS postural and gait score compared with non-carriers, although there was no statistical significance probably due to limited sample size. It is also possible that risk variant carriers would show more substantial motor progression if the follow-up duration were to be extended. In line with our hypothesis, Oosterveld et al. reported that PD patients in another independent cohort who harbored the same LRRK2 risk variant(s) presented greater motor progression after 4 years onwards (5) . It was reported that LRRK2 G2385R variant carriers presented more severe form of PD compared with G2019S and idiopathic PD patients (10) . Therefore, specific LRRK2 variants should be analyzed separately in clinical studies. However, it is not statistically feasible in our study due to insufficient subjects in each subgroup. In addition, when studying the effect of LRRK2 variant on PD progression, it is optimal to examine the status of other PD-related genes, which may be associated with LRRK2 and affect the risk of LRRK2-related PD, such as SNCA (11) and GBA (3).
In terms of non-motor symptoms and quality of life, transient differences were found in NMS total frequency, NMSS domain 3 (mood and apathy), and PDQ-39 domain 3 (emotional wellbeing) between non-carriers and risk variant carriers at early stage of the disease. This indicates progression course of nonmotor symptoms and quality of life in PD with risk variants may differ from non-carriers. These non-motor symptoms may have to be identified and addressed timely in PD patients carrying risk variants.
Our current prospective study provides comprehensive information on the progression of multifaceted clinical features in PD with Asian-related risk variants, including motor, non-motor symptoms, and quality of life. Our study found that progression of motor symptoms became faster in risk variant carriers after 4 years, whereas progression of nonmotor symptoms differed at early stage of disease between non-carriers and risk variant carriers, suggesting that LRRK2 carriers may need to be closely monitored and managed for clinical progression.
We acknowledge that sample size may be a potential limitation in our study, which may increase the risk of false positive error. Validation of our findings in larger cohort will be warranted.
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